

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

OCEAN BIO CHEM INC
Form 10-Q
August 14, 2007

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2007

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Commission File No. 0-11102

OCEAN BIO-CHEM, INC.

(Exact name of Registrant as specified in its charter)

Florida
(State or other jurisdiction of
incorporation or organization)

59-1564329
(I.R.S. Employer
Identification No.)

4041 SW 47 Avenue, Fort Lauderdale, Florida 33314-4023
954-587-6280

(Address and telephone number, including area code of
Registrant's Principal Executive Offices)

Securities registered pursuant to Section 12(b) of the Act:

Common stock, par value \$.01 per share

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

No

Indicate by check mark whether the Registrant (1) Is a Shell Company (As Defined In rule 12b-2 of the Exchange Act).

Yes

No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer (as defined by Rule 12b-2 of the Securities Exchange Act of 1934), or a non-accelerated filer

Large Accelerated Filer Accelerated Filer Non- Accelerated Filer

Indicate the number of shares outstanding of each class of the Issuer's common stock, as of the latest practicable date:

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

\$.01 par value common stock, 10,000,000 shares authorized,
7,723,316 shares issued and outstanding at August 9, 2007

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES

INDEX

Description	Page
Part I - Financial Information:	
Item 1. - Financial Statements:	
Consolidated balance sheets as of June 30, 2007 and December 31, 2006	3
Consolidated statements of operations for the three and six month periods ended June 30, 2007 and 2006	4
Consolidated statements of changes in shareholders' equity for the six months ended June 30, 2007 and 2006	5
Consolidated statements of cash flows for the six months ended June 30, 2007 and 2006	6
Notes to consolidated financial statements	7-12
Item 2. - Management's Discussion and Analysis of Financial Condition and Results of Operations	12-16
Item 3 - Quantitative and Qualitative Disclosures about Market Risk	16-17
Item 4 - Controls and Procedures	17-18
Part II - Other Information:	
Item 1. - Legal Proceedings	18
Item 2. - Unregistered Sales of Equity Securities and Use of Proceeds	18
Item 3. - Defaults upon Senior Securities	18
Item 4. - Submission of Matters to a Vote by Security Holders	18
Item 5. - Other Matters	18
Item 6. - Exhibits	18
Signatures	18
Certifications	19-21

PART I - Financial Information

Item 1. Financial Statements:

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

ASSETS

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

	JUNE 30, 2007
	----- (UNAUDITED)
Current assets:	
Cash	\$ 840,508
Trade accounts receivable net of allowance for doubtful accounts of approximately \$50,300 and \$192,700 at June 30, 2007 and December 31, 2006, respectively	2,479,135
Inventories (net)	6,513,007
Prepaid expenses and other current assets	269,486

Total current assets	10,102,136

Property, plant and equipment, net	6,486,378

Other assets:	
Trademarks, trade names and patents, net of accumulated amortization	331,695
Due from affiliated companies, net	-
Deposits and other assets	177,569

Total other assets	509,264

Total assets	\$17,097,778
	=====
LIABILITIES AND SHAREHOLDERS' EQUITY	
Current liabilities:	
Accounts payable - trade	\$ 1,235,278
Note payable - bank	3,000,000
Current portion of long term debt	586,555
Accrued expenses payable	719,192

Total Current Liabilities	5,541,025

Long term debt, less current portion	4,256,911

Shareholders' equity:	
Common stock - \$.01 par value, 10,000,000 shares authorized; 7,723,316 and 7,621,316 shares issued and outstanding at June 30, 2007 and December 31, 2006, respectively	77,233
Additional paid-in capital	7,423,121
Foreign currency translation adjustment	(209,939)
Retained earnings (deficit)	17,622
	7,308,037

Less treasury stock, 7,519 shares at cost	(8,195)

	7,299,842

Total liabilities and shareholders' equity	\$17,097,778
	=====

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

	FOR THE THREE MONTHS ENDED JUNE 30,		FOR
	2007	2006	2007
Gross sales	\$5,968,738	\$4,658,995	\$10,388,3
Allowances	534,735	327,486	931,9
Net sales	5,434,003	4,331,509	9,456,4
Cost of goods sold	3,275,260	3,154,032	6,122,7
Gross profit	2,158,743	1,177,477	3,333,6
Costs and expenses:			
Advertising and promotion	467,380	285,437	674,0
Selling and administrative	1,190,910	912,685	2,225,0
Interest expense	105,860	192,591	203,0
Total cost and expenses	1,764,150	1,390,713	3,102,1
Operating Income (loss)	394,593	(213,236)	231,4
Other income	-	-	-
Income (loss) before income taxes	394,593	(213,236)	231,4
Income taxes (benefit)	-	-	-
Net Income (loss)	394,593	(213,236)	231,4
Other comprehensive income (loss), net of tax			
Foreign currency translation adjustment	34,912	8,23	(33,8
Comprehensive income (loss)	\$ 429,505	(\$ 205,003)	\$ 197,6
Income (loss) per common share - basic	\$.06	(\$.03)	\$.
Income (loss) per common share - diluted	\$.05	(\$.03)	\$.

The Company has adopted Statement of Financial Accounting Standards No. 130 that requires items of comprehensive income to be stated as part of the basic financial statements. The only item of comprehensive income that the Registrant has is its foreign currency translation adjustment.

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

	Common stock Shares	Amount	Additional paid-in capital	Foreign currency adjustment	Retained earnings (deficit)	Tr
	-----	-----	-----	-----	-----	-----
January 1, 2007	7,621,316	\$76,213	\$7,257,447	(\$176,094)	(\$ 213,838)	
Net Income					231,460	
Common stock issuances	102,000	1,020	142,902			
Stock based compensation			22,772			
Foreign currency translation adjustment				(33,845)		
June 30, 2007	<u>7,723,316</u>	<u>\$77,233</u>	<u>\$7,423,121</u>	<u>(\$ 209,939)</u>	<u>\$ 17,622</u>	
January 1, 2006, as previously reported	5,849,316	\$58,493	\$4,908,615	(\$179,653)	(\$ 488,563)	
Compensation cost associated with the modification of stock options			178,332		(178,332)	
Compensation cost associated with stock warrants			310,898			
January 1, 2006, as restated	----- 5,849,316	----- 58,493	----- 5,397,845	----- (179,653)	----- (666,895)	
Net loss					(20,396)	
Debt forgiveness - affiliate			295,752			
Common stock issuances	129,000	1,290	118,132			
Stock based compensation			23,257			
Foreign currency translation adjustment				13,732		
June 30, 2006	<u>-----</u> 5,978,316	<u>-----</u> \$59,783	<u>-----</u> \$5,834,986	<u>-----</u> (\$ 165,921)	<u>-----</u> (\$ 687,291)	

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

5

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2007 AND 2006

	2007

Cash flows from operating activities:	
Net income (loss)	\$ 231,460
Adjustments to reconcile net income (loss) to net cash provided (used) by operations:	
Depreciation and amortization	388,498
Compensation cost associated with stock options and stock awards	166,694
Amortization of imputed interest	-
Decrease in accounts receivable - allowance for doubtful account	142,431
Changes in assets and liabilities:	
(Increase) in accounts receivable	(594,696)
(Increase) in inventory	(865,075)
(Increase) decrease in prepaid expenses	(26,650)
Increase in accounts payable and accrued taxes and other	644,898

Net cash provided by operating activities	87,560

Cash flows used by investing activities:	
Purchases of property, plant and equipment	(74,700)

Net cash used in investing activities	(74,700)

Cash flows from financing activities:	
Borrowings line of credit	1,300,000
Principal payments - line of credit	(448,002)
Decrease in amounts due from affiliates	231,200
Increase in Long-term debt	-
Principal payments long-term debt	(292,785)

Net cash provided (used) by financing activities	715,713

Increase (decrease) in cash prior to effect of exchange rate on cash	803,273
Effect of exchange rate on cash	(33,845)

Net increase (decrease) in cash	769,428

Cash at beginning of year	71,080

Cash at end of period	\$ 840,508
	=====
Supplemental disclosure of cash transactions:	
Cash paid for interest during period	\$ 208,579
	=====
Cash paid for income taxes during period	\$ -
	=====

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

Supplemental information-disclosure of non-cash transactions:

Compensation cost associated with stock options and warrants	\$ 22,772
	=====
Forgiveness of indebtedness to an affiliate	\$ -
	=====

The Company had no cash equivalents at June 30, 2007, and 2006.

6

OCEAN BIO-CHEM, INC. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. SUMMARY OF ACCOUNTING POLICIES

Interim Reporting

The accompanying unaudited consolidated financial statements include the accounts of Ocean Bio-Chem, Inc. and its subsidiaries ("the Company"). All significant inter-company transactions and balances have been eliminated. The unaudited consolidated financial statements have been prepared in conformity with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission and, therefore, do not include information or footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America. However, all adjustments (consisting of normal recurring accruals) that, in the opinion of management, are necessary for a fair presentation of the financial statements, have been included. Operating results for the period ended June 30, 2007 are not necessarily indicative of the results that may be expected for the future fiscal quarters in 2007 or the full year ending December 31, 2007 due to seasonal fluctuations in the Company's business, changes in economic conditions and other factors. For further information, please refer to the Consolidated Financial Statements and Notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2006.

Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates that affect the reported amount of assets, liabilities, revenues and expenses during the reporting period. Actual results could differ from those estimates.

Revenue recognition

Revenue from product sales is recognized when persuasive evidence of an arrangement exists, delivery to customer has occurred, the sales price is fixed and determinable, and collectibility of the related receivable is probable. Reported net sales are net of customer prompt pay discounts, contractual allowances, authorized customer returns, consumer rebates and other allowable deductions from our invoices. Cooperative advertising deductions, based on our customers' promotion of our products is recognized as an advertising cost and charged against operations as an operating expense.

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

Cost of goods sold/Selling, general and administrative expenses

Cost of goods sold includes all of the direct and indirect costs of manufacturing our products. Included therein specifically are warehousing costs of both raw and finished materials, in-bound freight, out-bound freight (in those instances that we absorb such costs), purchasing, receiving, and inspection costs. Other costs of the distribution network are reflected in Selling, General and Administrative expenses. Also included therein are managerial and clerical wages and related expenses, office and administrative occupancy costs, taxes, professional fees, insurance coverage's and other related expenses.

Inventories

Inventories are comprised of finished goods and stated at the lower of cost or market. Cost is determined by the first-in, first-out method. The composition of inventories at June 30, 2007 and December 31, 2006 were as follows:

	2007	2006
	----	----
Raw materials	\$ 2,252,656	\$ 3,423,030
Finished goods	4,310,351	2,244,903
Less Inventory Reserve	(50,000)	(20,000)
	-----	-----
Inventory - net	\$ 6,513,007	\$ 5,647,933
	=====	=====

7

Stock Based Compensation

At June 30, 2007, The Company had options outstanding under four stock-based compensation plans, which are described below. On January 1, 2006, The Company adopted Statement of Financial Accounting Standards No. 123, "Share Based Payment" ("SFAS No. 123R"), which requires the measurement and recognition of compensation cost for all share-based payment awards made to employees and directors based on estimated fair values.

The Company has elected to use the modified prospective transition method for adopting SFAS No. 123R, which requires the recognition of stock-based compensation cost on a prospective basis; therefore, prior period financial statements have not been restated. Under this method, the provisions of SFAS No. 123R are applied to all awards granted after the adoption date and to awards not yet vested with unrecognized expense at the adoption date based on the estimated fair value at grant date as determined under the original provisions of SFAS No. 123. The impact of forfeitures that may occur prior to vesting is also estimated and considered in the amount recognized. In addition, the realization of tax benefits in excess of amounts recognized for financial reporting purposes will be recognized as a financing activity rather than an operating activity as in the past.

Stock Compensation Plans

Under various plans, The Company may grant incentive or non-qualified stock options to employees and directors. The terms of stock options granted under the plans are determined by the Company's Board of Directors at the time of grant, including the exercise price, term and any restrictions on the exercisability of such option. The exercise price of all options granted under the plans equals the market price at the date of grant, except for options granted to Mr. Dornau, our President and CEO, which are generally granted at a premium of 10% above the market price of the underlying common stock, and no option is exercisable after

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

the expiration of five or ten years from the date of grant, depending on the Plan under which it was awarded. The stock options outstanding under our qualified or incentive plans were generally granted for terms of five years and vest on a straight line basis over such period. The stock options outstanding under our 2002 non qualified plan were generally granted for terms of ten years and vested immediately. No employee compensation expense was recognized in the financial statements upon either the grant or exercise of these stock options.

As of June 30, 2007, the number of options outstanding and the number of shares available for grant under each Stock Option Plan and non-plan options is presented below:

Plan	Options outstanding	Options available for grant
1994 Plan	159,500 shares	None - terminated 2004
2002 Plan	400,000 shares	None
2002 Non-qualified Plan	155,000 shares	45,000 shares
2007 Plan	164,500 shares	235,500 shares
Non-plan options	231,000 shares	N/A
	----- 1,110,000 shares =====	

Information with respect to our Stock Option Plan activity is as follows:

	Shares	Weighted average exercise price
Outstanding at December 31, 2006	945,500	\$1.21
Granted	164,500	\$1.66
Exercised	-	-
Forfeited	-	-
Outstanding at June 30, 2007	----- 1,110,000 =====	----- \$1.27 =====

8

For the six-month period ended June 30, 2007, The Company recognized \$22,772 in stock-based compensation costs, which is reflected in operating expenses. No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets. The Company elected to adopt the alternative method of calculating the historical pool of windfall tax benefits as permitted by FASB Staff Position (FSP) No. SFAS 123R-c, "Transition Election Related to Accounting for the Tax Effects of Share-Based Payment Awards." This is a simplified method to determine the pool of windfall tax benefits that is used in determining the tax effects of stock compensation in the results of operations and cash flow reporting for awards that were outstanding as of the adoption of SFAS No. 123R. As of June 30, 2007, The Company had \$224,467 of unrecognized compensation costs related to non-vested stock option awards that is expected to be recognized over a weighted average period of 5 years.

The following information applies to options outstanding and exercisable as of June 30, 2007:

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

Options:	Options outstanding	Exercisable 06/30/07	Exercise price
	-----	-----	-----
Non Plan Options	231,000	231,000	.760
1994 Plan	159,500	63,800	1.050
2002 Plan	125,000	100,000	1.260
2002 Plan	140,000	84,000	1.620
2002 Plan	135,000	-	0.930
2007 Plan	164,500	-	1.660
2002 Plan (NQ)	35,000	35,000	1.260
2002 Plan (NQ)	40,000	40,000	1.030
2002 Plan (NQ)	40,000	40,000	1.460
2002 Plan (NQ)	40,000	40,000	1.090
	-----	-----	
	1,110,000	633,800	
	=====	=====	

The Company utilizes a Black-Scholes option-pricing model to determine the fair value of stock options on the date of grant. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield. The Company's expected volatility is based on the historical volatility of The Company's stock price over the most recent period commensurate with the expected term of the stock option award. The estimated expected option life is based primarily on historical employee exercise patterns and considers whether and the extent to which the options are in-the-money. The risk-free interest rate assumption is based upon the U.S. Treasury yield curve appropriate for the term of The Company's stock options awards and the selected dividend yield assumption was determined in view of The Company's historical and estimated dividend payout. The Company has no reason to believe that the expected volatility of its stock price or its option exercise patterns will differ significantly from historical volatility or option exercises.

Restricted Stock Awards as Compensation:

During May 2007 we issued 102,000 shares of our common stock bearing a restricted legend to certain officers and other key employees as a component of their compensation. At the date of grant the shares had a market value of \$1.66 each. Shares were awarded as follows:

Officers:

Peter G. Dornau, President and CEO	15,000 shares
Jeffrey Barocas, Vice President and CFO	5,000 shares
William Dudman, Vice President	15,000 shares
Gregor M. Dornau	15,000 shares

	50,000 shares
Other employees, as a group (16 individuals)	52,000 shares

Total restricted shares awarded	102,000 shares
	=====

These restricted stock awards were approved by our shareholders at our Annual Meeting of Shareholders held on August 3, 2007. The Company recorded approximately \$144,000 of compensation expense in the second quarter 2007. In the second quarter ended June 30, 2006 the Company issues 129,000 shares of restricted stock at market value of \$1.08 per share, bearing a restricted legend to certain officers and other key employees as a component of their compensation. 105,000 shares were issues to officers and 24,000 shares were issues to other employees

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

9

2. PROPERTY, PLANT & EQUIPMENT

The Company's property, plant and equipment consisted of the following at June 30, 2007 and December 31, 2006:

	Estimated Useful Life- Years	2007	2006
Land	N/A	\$ 278,325	\$ 278,325
Building	30	4,389,154	4,389,154
Manufacturing and warehouse equipment	6-20	6,563,590	6,563,590
Office equipment and furniture	3-5	707,420	707,420
Construction in process	N/A	20,307	20,307
Leasehold improvement	10-15	178,403	178,403
		-----	-----
		12,137,199	12,137,199
Less accumulated depreciation		5,650,821	5,650,821
		-----	-----
Total property, plant and equipment, net		\$ 6,486,378	\$ 6,486,378
		=====	=====

3. LONG-TERM DEBT

Long-term debt at June 30, 2007 consisted of the following:

The Company is obligated pursuant to capital leases financed through Industrial Development Bonds. Such obligations were incurred during 1997 and 2002 in connection with building and equipment expansion at the Company's Alabama manufacturing and distribution facility. Both bear interest at tax-free rates that adjust weekly. At June 30, 2007, \$1,613,108 and \$2,900,000 were outstanding attributable to the 1997 and 2002 series, respectively. During the six months ended June 30, 2007 interest rates ranged between 3.3% and 3.7%. Principal and accrued interest retiring the underlying bonds are payable quarterly through March, 2012 and July, 2017 for the 1997 and 2002 series, respectively. Repayment of the bonds is guaranteed by a Letter of Credit issued by the Company's primary commercial bank. Security for the Letter of Credit is a priority first mortgage on the Kinpak facility and manufacturing equipment.

The company, through its subsidiary, Kinpak Inc., is obligated pursuant to various capital lease agreements covering equipment utilized in the Company's Alabama plant. Such obligations, aggregating approximately \$26,559 at June 30, 2007, have varying maturities through 2009 and carry interest rates ranging from 7% to 12%.

During April 2005 we entered into a financing obligation with Regions Bank whereby they advanced \$500,000 to the Company in order to finance equipment acquisitions at our Kinpak facility. Such obligation is due in monthly installments of principal aggregating approximately \$8,300 plus interest at prevailing rates (the outstanding balance and interest rate on this obligation at June 30, 2007 were approximately \$283,300 and 7.6% per annum, respectively) through maturity on April 15, 2010.

During the quarter ended December 31, 2005, we finalized a \$1.5 million

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

revolving credit facility with our president and CEO, Peter G. Dornau. At June 30, 2006 the gross obligation aggregating \$1,150,000 was outstanding pursuant to this obligation, which is due in October 2010 along with accrued interest at the rate of prime plus 2%. In connection with his offering this financing arrangement to the Company, we issued warrants to Mr. Dornau to purchase a maximum of 1 million shares of our common stock. Such warrants are exercisable 500,000 shares at \$1.13 and 500,000 shares at \$.863. The exercise prices were determined by the closing bid of our stock plus ten (10) percent on each date of grant. In addition, he has the right, at his sole discretion, to convert such debt into a maximum of 1.5 million shares of our common stock at the rate of \$1.00 per share. The gross obligation was reduced by an allocation of imputed interest associated with the warrants issued to Mr. Dornau. The initial amount of such allocation was \$310,898 which will be amortized and charged against operations as additional interest expense over the sixty (60) month term of this financing. During the six months ended June 30, 2006, amortization of \$31,090 was charged against operations. This obligation is subordinate to all borrowings from Regions Bank.

10

On November 10, 2006, our President and CEO, Peter G. Dornau indicated that he was exercising his right to convert our indebtedness to him into common stock pursuant to the terms of the Subordinated Revolving Line of Credit he entered into with the Company. Our total long-term debt was reduced and shareholders' equity was increased by approximately \$1,241,000, respectively.

The composition of these obligations at June 30, 2007 and December 31, 2006 were as follows:

	Current Portion		Long Term Portion	
	2007	2006	2007	2006
Industrial Development Bonds	\$ 460,000	\$ 460,000	\$ 4,053,108	\$ 4,283,108
Notes payable	99,996	99,996	183,346	233,346
Capitalized equipment leases	26,559	26,064	20,457	33,700
	-----	-----	-----	-----
	\$ 586,555	\$ 586,060	\$ 4,256,911	\$ 4,550,154
	=====	=====	=====	=====

Required principal payment obligations as of June 30, 2007 attributable to the foregoing are tabulated below:

2007	\$ 586,555
2008	579,490
2009	572,051
2010	495,540
2011	460,000
Thereafter	2,149,830

Total	\$4,843,466
	=====

4. RELATED PARTY TRANSACTIONS

At June 30, 2007 and December 31, 2006, the Company had amounts receivable from and payable to affiliated companies, which are directly or beneficially owned by the Company's president, aggregating a net payable of approximately \$

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

5,524 and receivable of \$231,200 respectively. Such amounts result from sales to the affiliates, allocations of expenses incurred by the Company on the affiliates' behalf and funds advanced to or from the Company.

Sales to such affiliates aggregated approximately \$270,934 and \$404,109 during the six months ended June 30, 2007 and 2006, and \$74,256 and 110,109 for the three months ended June 30, 2007 and 2006, respectively.

During March 2006, an affiliate offered to forgive the Company's indebtedness to such entity in the approximate amount of \$295,000. Accordingly, during the first quarter of 2006, such amount was credited to Additional paid-in capital and increased the net amount due from affiliates.

Commitments:

On May 1, 1998, the Company entered into a ten year lease for approximately 12,700 square feet of office and warehouse facilities in Fort Lauderdale, Florida from an entity owned by certain officers of the Company. The lease required a minimum rental of \$94,800 for the first year and provides for a maximum 2% increase on the anniversary of the lease throughout the term, which has been waived through December 31, 2006. Additionally, the landlord is entitled to its pro-rata share of all taxes, assessments, and any other expenses that arise from ownership. Rent charged to operations aggregated approximately \$53,500 and \$50,200 during the six months ended June 30, 2007 and 2006, and \$25,100 and \$25,100 during the three months ended June 30, 2007 and 2006, respectively.

The Company has entered into a corporate guaranty of a mortgage note obligation of such affiliate. The obligation aggregating approximately \$290,000 and \$306,000 at June 30, 2007 and 2006 and December 31, 2006, respectively is primarily secured by the real estate leased to the Company.

11

The following is a schedule of minimum future rentals on the non-cancelable operating leases.

Year ending December 31, :	
2007	\$ 106,597
2008	36,243
2009	-
2010	-
Thereafter	-

Total	\$ 142,840
	=====

5. EARNINGS (LOSS) PER SHARE

	Three months ended June 30,		Six months ended June	
	2007	2006	2007	2006
	-----	-----	-----	-----
Weighted-average common shares outstanding	7,689,316	5,978,316	7,655,316	5,978,316
Dilutive effect of stock plans, other options & conversion rights	883,060	523,476	838,060	523,476
	-----	-----	-----	-----
Diluted weighted-average shares				

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

outstanding	8,572,376	6,501,792	8,538,376
	=====	=====	=====

Forward-looking Statements:

Certain statements contained herein, including without limitation expectations as to future sales and operating results, constitute forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigations Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "expect", "anticipate", "intend", "could" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that may affect the Company's results include, but are not limited to, the highly competitive nature of the Company's industry; reliance on certain key customers; consumer demand for marine recreational vehicle and automotive products; advertising and promotional efforts, and other factors. The Company will not undertake and specifically declines any obligation to update or correct any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Item 2. Management's Discussion and Analysis of Financial Conditions and Results of Operations

Overview:

We are a leading manufacturer and distributor of chemical formulations serving the appearance and functional categories of the marine, automotive, recreational vehicle and home care markets. We were founded in 1973 and have conducted operations within the aforementioned categories since then. During 1984, we changed our corporate name to Ocean Bio-Chem, Inc. (the parent company) from our former name, Star Brite Corporation. Our operations were conducted as a privately owned company through March, 1981 when we completed our initial public offering of common stock.

12

Critical accounting policies and estimates:

Principles of consolidation - Our consolidated financial statements include the accounts of the parent company and its wholly owned subsidiaries. All significant inter-company accounts and transactions are eliminated in consolidation.

Revenue recognition - Revenue from product sales is recognized when persuasive evidence of an arrangement exists, delivery to customer has occurred, the sales price is fixed and determinable, and collectibility of the related receivable is probable.

Prepaid advertising and promotion - In any given year we introduce certain new products to our customers. We produce new promotional items to be distributed over a period of time. We follow the policy of amortizing these costs as a promotional expense as they are consumed. Advertising is expensed in the period the advertisement is run.

Property, plant and equipment - Property, plant and equipment are stated at

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

cost. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method.

Stock based compensation - Prior to January 1, 2006 we followed the provisions of APB Opinion No. 25, Accounting for Stock Issued to Employees, to record compensation costs. Opinion No. 25 requires that compensation cost be based on the difference, if any, between the quoted market price of the stock and the price the employee must pay to acquire the stock depending on the terms of the award. Effective January 1, 2006 we adopted the provisions Statement of Financial Accounting Standards No. 123R to record such compensation costs. Prior thereto, such matters were disclosed in the notes to our consolidated financial statements.

Concentration of credit risk - Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of accounts receivable. Over the past three years, our five largest customers historically represented a range of approximately 45% to 55% of consolidated gross revenues and 25% to 77% of consolidated accounts receivable, respectively. We have experienced a longstanding relationship with each of these entities and have always collected open receivable balances in a timely manner. However, the loss of any of these customers could have an adverse impact on our operations.

Fair value of financial instruments - The carrying amount of cash approximates its fair value. The fair value of long-term debt is based on current rates at which we could borrow funds with similar remaining maturities, and the carrying amount approximates fair value.

Income taxes - We file consolidated federal and state income tax returns. We have adopted Statement of Financial Accounting Standards No. 109 and FIN 48 in the accompanying consolidated financial statements. The only temporary differences included therein are attributable to differing methods of reflecting depreciation for financial statement and income tax purposes.

Trademarks, trade names and patents - The Star Brite trade name and trademark were purchased in 1980 for \$880,000. The cost of such intangible assets was amortized on a straight-line basis over an estimated useful life of 40 years through December 31, 2001. Effective January 1, 2002 and pursuant to Statement of Financial Accounting Standards No. 142, we have determined that the carrying value of such intangible assets relating to its Star Brite brand does not require further amortization. In addition, we own two patents that we believe are valuable in limited product lines, but not material to our success or competitiveness in general. There are no capitalized costs of these two patents.

Translation of Canadian currency - The accounts of our Canadian subsidiary are translated in accordance with Statement of Financial Accounting Standards No. 52, which requires that foreign currency assets and liabilities be translated using the exchange rates in effect at the balance sheet date. Results of operations are translated using the average exchange rate prevailing throughout the period. The effects of unrealized exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars are accumulated as the translation adjustment in shareholders' equity. Realized gains and losses from foreign currency transactions, if any, are included in net earnings of the period.

13

Liquidity and Capital Resources:

The primary sources of our liquidity are our operations and short-term

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

borrowings from Regions Bank pursuant to a revolving line of credit aggregating \$6 million. Such line matures May 31, 2008, bears interest at the 30 Day LIBOR plus 275 basis points (approximately 7.9% at June 30, 2007) and is secured by our trade receivables, inventory and intangible assets. As of each year-end, December 31, we are required to maintain a minimum working capital of \$1.5 million and meet certain other financial covenants during the term of the agreement. As of June 30, 2007, we were obligated under this arrangement in the amount of \$3,000,000.

In connection with the purchase and expansion of the Alabama facility, we closed on Industrial Development Bonds during 1997 aggregating approximately \$5 million. The proceeds were utilized for both the repayment of certain advances used to purchase the Alabama facility and to expand such facility. During July 2002, we completed a second Industrial Development Bond financing aggregating \$3.5 million through the City of Montgomery, Alabama. Such transaction funded an approximate 70,000 square foot addition to the manufacturing facility as well as the remaining machinery and equipment additions required therein. This project was substantially completed during 2003.

In order to market the Industrial Development Bonds at favorable rates, we obtained a substitute irrevocable letter of credit for the 1997 issue and a new irrevocable letter of credit for the 2002 issue. Under such letters of credit agreements, maturing on July 31, 2008, we are required to maintain a stipulated level of working capital, a designated maximum debt to tangible ratio, and a required debt service coverage ratio. Such letters of credit are secured by a first priority mortgage on the underlying Alabama facility and equipment.

The bonds are marketed weekly at the prevailing rates for such tax-exempt instruments. During the six months ended June 30, 2007 such bonds carried interest ranging between 3.3% and 3.7% annually. Interest and principal are payable quarterly. We believe current operations are sufficient to meet these obligations.

On April 12, 2005 we entered into a financing obligation with Regions Bank whereby they advanced us \$500,000 to finance equipment acquisitions at our Kinpak facility. Such obligation is due in monthly installments of principal aggregating approximately \$8,300 plus interest at prevailing rates (the outstanding balance and interest rate on this obligation at June 30, 2007 were approximately \$283,300. The maturity on this obligation is April 15, 2010.

During the quarter ended December 31, 2005, we finalized a \$1.5 million revolving credit facility with our president and CEO, Peter G. Dornau. At June 30, 2006, the gross obligation aggregating was \$1,275,000 outstanding pursuant to this obligation which is due in October 2010 along with accrued interest at the rate of prime plus 2%. In connection with his offering this financing arrangement to the Company, we issued warrants to Mr. Dornau to purchase a maximum of 1 million shares of our common stock. Such warrants are exercisable 500,000 shares at \$1.13 and 500,000 shares at \$.863. The exercise prices were determined by the closing bid of our stock plus ten (10) percent on each date of grant. In addition, he has the right, at his sole discretion, to convert such debt into a maximum of 1.5 million shares of our common stock at the rate of \$1.00 per share. The gross obligation was reduced by an allocation of imputed interest associated with the warrants issued to Mr. Dornau. The initial amount of such allocation was \$310,898 which will be amortized and charged against operations as additional interest expense over the sixty (60) month term of this financing. During the six months ended June 30, 2006, amortization of \$31,090 was charged against operations. This obligation is subordinate to all borrowings from Regions Bank.

On November 10, 2006, our President and CEO, Peter G. Dornau indicated that he was exercising his right to convert our indebtedness to him into common stock pursuant to the terms of the Subordinated Revolving Line of Credit he entered

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

into with the Company. Our total long-term debt was reduced and shareholders' equity was increased by approximately \$1,241,000, respectively.

We are involved in making sales in the Canadian market and must deal with the currency fluctuations of the Canadian currency.

We do not engage in currency hedging and deal with such currency risk as a pricing issue.

14

During the past few years, we have introduced various new products to our customers. At times this has required us to carry greater amounts of overall inventory and has resulted in lower inventory turnover rates. The effects of such inventory turnover have not been material to our overall operations. We believe that all required capital to maintain such increases can continue to be provided by operations and current financing arrangements.

Many of the raw materials that we use in the manufacturing process are commodities that are subject to fluctuating prices. We react to long-term increases by passing along all or a portion of such increases to our customers.

As of June 30, 2007 and through the date hereof, we did not and do not have any material commitments for capital expenditures, nor do we have any other present commitment that is likely to result in our liquidity increasing or decreasing in any material way. In addition, except for our need for additional capital to finance inventory purchases, we know of no trend, additional demand, event or uncertainty that will result in, or that is reasonably likely to result in, our liquidity increasing or decreasing in any material way.

On March 25, 1999, the Company entered into a loan arrangement with an entity owned 50% each by our President and former Vice President - Advertising, Messrs. Peter G. Dornau and Jeffrey J. Tieger, respectively whereby we borrowed \$400,000.00 to be repaid in monthly installments of \$3,356.79 plus prevailing interest at prime plus 1%. On March 9, 2006 we received notification from the shareholders of said entity that they were forgiving this obligation and, accordingly, the Company has no further obligation associated with this debt. At that date the principal balance outstanding amounted to \$295,752 and such amount is reflected on the accompanying consolidated statement of shareholders' equity as additional paid-in capital.

Results of Operations:

For The Three Months Ended June 30, 2007 compared to the Three Months ended June 30, 2006

Net sales increased approximately \$1,102,000 or 25.5 % for the quarter ended June 30, 2007 compared to the same quarter of the preceding year. The consolidated net sales aggregated approximately \$5,434,000 and \$4,331,500 respectively. Sales increases were a result of the improved boating weather in the 2nd quarter of 2007, in addition to increased sales of newer products in both the boating and auto care markets.

Cost of goods sold amounted to approximately \$3,275,000 or 60.3 % of net sales for the three months ended June 30, 2007 compared to \$3,154,000 or 72.8% of net sales for the quarter ended June 30, 2006. These results were favorably effected by increased sales volume and changes in the sales mix with higher sales of the Company's higher margin products. In addition, the cost of sales were favorably impacted as the result of spreading fixed element of manufacturing overhead over increased volume during the current quarter.

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

Selling and administrative expenses increased approximately \$278,000 to \$1,191,000 or 21.9% of sales when comparing the quarters ended June 30, 2007 compared to \$912,685 for 2006. The significant increases were a charge to income in the quarter for compensation expense relating to the awarding of Ocean Bio-Chem stock to employees of approximately \$144,000. In addition to increased personnel costs, consulting fees, outside services, other professional fees and outsourced data processing services.

Advertising and promotion increased to approximately \$467,000 an increase of \$182,000 or approximately 63.7 % from \$285,400 for 2006. The increased spending correlated with increased sales and the resulting customer co-operative advertising programs related to sales. In addition, the Company placed increased levels of TV media and print advertising during the current three month period.

Interest expense decreased by approximately \$86,700 comparing the quarter ended June 30, 2007 compared to the corresponding quarter in 2006. This principally resulted from conversion of a loan to equity in the 4th quarter 2006, to our Company by our president and CEO, Peter G. Dornau, reducing debt by \$1,241,000 and associated interest expense.

Our net income for the quarter ended June 30, 2007 amounted to \$394,593 compared to a loss of \$213,236 for the comparable period in 2006. There was no provision or benefit for income taxes in the current quarter due to consideration of available Income Tax carryovers.

15

For the Six Months Ended June 30, 2007 Compared To The Six Months Ended June 30, 2006

Net sales increased 8.2% to approximately \$9,456,400 for the six months ended June 30, 2007 compared to approximately \$8,741,100 for the six months ended June 30, 2006. The significant increase in year to date sales were in the second quarter 2007 as discussed above.

Cost of goods sold decreased to 64.6% of net sales for the six months ended June 30, 2007 compared to 71.1% of net sales for the six months ended June 30, 2006. This change resulted was attributed improved sales mix and volume along with spreading our fixed element of manufacturing overhead over the higher sales levels experienced during the six current month period.

Advertising and promotion expenses increased to \$674,000 or 7.1% of sales for the 2007 compared to 472,400 or 5.4% of net sales for the previous year. This increase in the current year was the result of increased sales and the resulting co-operative advertising programs related to sales. In addition, the Company placed increased levels of media and print advertising during the six month period.

Selling and administrative expenses increased to approximately \$2,225,000 for the six months ended June 30, 2007 compared to \$1,740,800 the six months ended June 30, 2006 an increase of \$484,281 or 27.8%. The significant increase was charge to income of \$ 144,000 for the awarding of stock of Ocean Bio-Chem to employees. In addition personnel costs, consulting fees, outside services, other professional fees and outsourced data processing services increased from prior year.

Interest expense for the 2007 decreased \$123,600 when compared to the same six month period of 2006. This principally resulted the conversion of a loan made by our President, Peter G. Dornau, to the Company to equity during the quarter ended December 31, 2006. Such conversion reduced long-term debt by approximately \$1,241,000 along with a related reduction in our interest expense.

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

The profit was approximately \$231,460 for the six months ended June 30, 2007 compared to a net loss of approximately \$20,400 for the six months ended June 30, 2006.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Market risk represents the risk of loss that may impact our financial position, results of operations or cash flows due to adverse changes in financial and commodity, principally petroleum based raw materials, market prices and interest rates. We are exposed to market risk in the areas of changes in borrowing rates in the United States and changes in foreign currency exchange rates. Historically, and as of June 30, 2007, we have not used derivative instruments or engaged in hedging activities to minimize market risk.

Interest rate risk

As of June 30, 2007, we had floating interest rates on our industrial development revenue bonds and our working capital line of credit facility. As of June 30, 2007 the interest rate on our approximate \$4,513,100 outstanding balance of industrial revenue bonds was approximately 3.7% per annum and the interest rate on our line of credit facility was based on the 30 day LIBOR rate plus 275 basis points (the effective interest rate at June 30, 2007 was 7.9%). We do not expect any changes in interest rates to have a material impact on our operations during the year ending December 31, 2007.

Concentration of credit risk

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of accounts receivable. The Company's five largest customers represented approximately 59%, and 57% of consolidated gross revenues for the six months ended June 30, 2007 and 2006; and 64% and 56% of consolidated accounts receivable at June 30, 2007 and 2006, respectively. The Company has a longstanding relationship with each of these entities and has always collected open receivable balances. However, the loss of any of these customers could have an adverse impact on the Company's operations.

16

Foreign currency risk

We sell products in Canada, based on the Canadian dollar. Thereby, we have exposure to changes in exchange rates. Changes in the Canadian dollar/U.S. dollar exchange rates may positively or negatively affect our gross margins, operating income and retained earnings. We do not believe that near-term changes in the exchange rates, if any, will result in a material effect on our future earnings, fair values or cash flows, and therefore, we have chosen not to enter into foreign currency hedging transactions. We cannot assure you that this approach will be successful, especially in the event of a significant and sudden change in the value of the Canadian dollar.

Concentration and credit risk

We maintain cash balances at several financial institutions, which are insured by the Federal Deposit Insurance Corporation up to \$100,000. At times, our cash balances may exceed federally insured limits. We have not experienced any losses in such accounts and we believe the risk related to these deposits is minimal.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. We have carried out an evaluation under the supervision of management, including the President and Chief Executive Officer ("CEO") and the Chief Operating Officer and Chief

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

Financial Officer ("CFO"), of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our CEO and CFO have concluded that, as of June 30, 2007, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Securities Exchange Act of 1934, as amended, was recorded, processed, summarized and reported within the time periods specified in the rules and regulations of the SEC, and include controls and procedures designed to ensure that information required to be disclosed by us in such reports was accumulated and communicated to management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosures.

Since the evaluation date by management of our internal controls over financial reporting, there have not been any changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

Limitations on the Effectiveness of Controls. Our management, including the CEO and CFO, does not expect that our disclosure or internal controls will prevent all errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Despite these limitations, our CEO and CFO have concluded that our disclosure controls and procedures (1) are designed to provide reasonable assurance of achieving their objectives and (2) do provide reasonable assurance of achieving their objectives.

Recent Accounting Pronouncements. In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities. SFAS No. 159 permits entities to choose to measure eligible financial instruments at fair value. The unrealized gains and losses on items for which the fair value option has been elected should be reported in earnings. The decision to elect the fair value options is determined on an instrument-by-instrument basis, it should be applied to an entire instrument, and it is irrevocable. Assets and liabilities measured at fair value pursuant to the fair value option should be reported separately in the balance sheet from those instruments measured using another measurement attribute. SFAS No. 159 is effective as of the beginning of the first fiscal year that begins after November 15, 2007. The Company is currently analyzing the potential impact of adoption of SFAS No. 159 to its consolidated financial statements.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements, ("SFAS 157"). Such pronouncement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. SFAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007 and interim periods within those fiscal years. The Company does not anticipate adoption of this standard will have a material impact on its consolidated financial statements.

In May 2007, the FASB issued FASB Staff Position ("FSP") FIN 48-1, or "FSP FIN 48-1," which clarifies when a tax position is considered settled under FIN 48. The FSP explains that a tax position can be effectively settled on the completion of an examination by a taxing authority without legally being extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if (1) the tax position is not considered more likely than not to be sustained solely on the basis of its

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

technical merits and (2) the statute of limitations remain open. FSP FIN 48-1 should be applied upon the initial adoption of FIN 48. The impact of our adoption of FIN 48 (as of January 1, 2007) is in accordance with this FSP and the implementation has not resulted in any changes to our consolidated financial statements.

PART II - OTHER INFORMATION

Item 1. - Legal Proceedings:

We are not a party to any material litigation presently pending nor, to the best knowledge of the Company, have any such proceedings been threatened.

Item 1A. - Risk Factors

Set forth any material changes from Risk Factors as previously reported in the Registrant's Form 10-K in response to Item 1A. in Part 1 of Form 10-K.

There have been no material changes

Item 2. - Unregistered Sales of Equity Securities and Use of Proceeds:

During May 2007 we issued 102,000 shares of our common stock bearing a restricted legend to certain officers and other key employees as a component of their compensation. At the date of grant the shares had a market value of \$1.66 each.

Item 3. - Defaults Upon Senior Securities: Not applicable

Item 4. - Submission of Matters to Vote of Security Holders:

On August 3, 2007, at our annual meeting of shareholders, nine directors; Peter G. Dornau, Edward Anchel, Jeffrey S. Barocas, Greg Dornau, William Dudman, Laz L. Schneider, James M. Kolisch, John B. Turner, and Sonia B. Beard were elected, shareholders ratified issuances of restricted common stock to certain employees, approval of the 2007 Incentive Stock Option Plan, and approved Berenfeld, Spritzer, Shechter & Sheer, Certified Public Accountants & Consultants, as independent auditors for the year ending December 31, 2007.

The tabulation of voting for the foregoing was as follows:

	For	Against/absta
Election of directors	6,967,321	6,532
Approve 2007 Incentive stock option plan	5,246,986	64,765
Approve and ratify grants of the Company's restricted stock	5,246,994	64,823
Ratify appointment of Berenfeld, Spritzer, Shechter & Sheer as independent CPA through December 31, 2007	6,967,437	6,461

Item 5. - Other matters: Not applicable

Item 6. - Exhibits:

31.1 Certification of Chief Executive Officer pursuant to Section 302 of Sarbanes-Oxley

31.2 Certification of Chief Financial Officer pursuant to Section 302 of Sarbanes-Oxley

32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of Sarbanes-Oxley

SIGNATURES

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on behalf by the Undersigned there unto duly authorized.

OCEAN BIO-CHEM, INC.

Date: August 14, 2007

/s/ Peter G. Dornau

Peter G. Dornau
Chairman of the Board of Directors
and Chief Executive Officer

/s/ Jeffrey S. Barocas

Jeffrey S. Barocas
Chief Financial Officer

18

Exhibit 31.1

CERTIFICATION

I, Peter G. Dornau certify that:

1. I have reviewed this Form 10-Q of Ocean Bio-Chem, Inc. as of and for the period ended June 30, 2007;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: August 14, 2007

/s/ Peter G. Dornau

Peter G. Dornau
Chairman of the Board and
Chief Executive Officer

19

Exhibit 31.2

CERTIFICATION

I, Jeffrey S. Barocas certify that:

1. I have reviewed this Form 10-Q of Ocean Bio-Chem, Inc. as of and for the period ended June 30, 2007;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: August 14, 2007

/s/ Jeffrey S. Barocas

Jeffrey S. Barocas
Chief Financial Officer

20

Exhibit 32.1

CERTIFICATION

Pursuant to 18U.S.C. Section 1350, the undersigned officers of Ocean Bio-Chem, Inc. (the "Company"), hereby certify that the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 (the "Report") fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Dated: August 14, 2007

/s/ Peter G. Dornau

Edgar Filing: OCEAN BIO CHEM INC - Form 10-Q

Peter G. Dornau
Chairman of the Board of
Directors and Chief Executive Officer

/s/ Jeffrey S. Barocas

Jeffrey s. Barocas
Chief Financial Officer